Dostarlimab with chemo and radiation for advanced womb cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You understand the study and sign consent before any study tests or treatment.
- Your endometrial cancer has been surgically staged (womb removed and lymph nodes checked) and confirmed as stage IIIC.
- You start treatment soon after surgery (enrolled within 8 weeks and first treatment within 10 weeks).
- You’re 18 or older, and your day-to-day functioning is good (ECOG 0–1).
- Recent blood tests are strong enough (hemoglobin, platelets, and neutrophils meet limits).
- Your kidneys, liver, and blood clotting tests are within allowed ranges, and you can wait at least a few weeks after surgery/radiation/chemo before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This trial studies a new drug called cadonilimab combined with chemotherapy for women with endometrial cancer that has come back or spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial compares continuing immunotherapy (pembrolizumab or dostarlimab) as maintenance therapy versus stopping it in people with advanced or recurrent endometrial cancer who have already completed standard chemotherapy and immunotherapy. The goal is to see if continuing improves survival.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.